OUR NEWSROOM
The central hub for company news and information.
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology
Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement
BOSTON, October 24, 2023 (GLOBE NEWSWIRE)
Elektrofi, Inc., a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic therapies, announced today that it has entered a multi-target research collaboration and license agreement with Eli Lilly and Company to develop next-generation medicines that can be delivered subcutaneously.
Elektrofi Appoints Victoria Sluzky as Chief Technology Officer to Drive Innovation and Technical Excellence
BOSTON, July 17, 2023 (GLOBE NEWSWIRE)
Today Elektrofi, a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic therapies, appointed Victoria Sluzky as Chief Technology Officer (CTO).
Elektrofi Strengthens Leadership Team with Appointments of Greg DeFilippis as Chief Business Officer and Paulette Gangemi as Chief Human Resources Officer
BOSTON, February 15, 2023 (GLOBE NEWSWIRE)
Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the appointment of pharmaceutical and medical device expert Greg DeFilippis as Chief Business Officer.
Elektrofi Announces Collaboration with Thermo Fisher Scientific to Strengthen Manufacturing Capabilities for Future Clinical Trials
Elektrofi announces collaboration with Thermo Fisher Scientific
Elektrofi Raises $40 Million Financing to Establish GMP Manufacturing Capabilities for Upcoming Clinical Studies and Expand Development Pipeline
Elektrofi raises $40 million financing to establish GMP manufacturing capabilities
Elektrofi Enters Global Collaboration and License Agreement with Argenx to Explore New Subcutaneous Product Formulations
The agreement provides argenx access to Elektrofi’s breakthrough high-concentration, low-volume delivery technology for the development of therapeutic products.